The role of transforming growth factor. in a prostatic fibrosis under suppression of dihydrotestosterone in high fat diet induced obesity rat model

You have accessJournal of UrologyCME1 Apr 2023PD02-02 THE ROLE OF TRANSFORMING GROWTH FACTOR Β IN A PROSTATIC FIBROSIS UNDER SUPPRESSION OF DIHYDROTESTOSTERONE IN HIGH FAT DIET INDUCED OBESITY RAT MODEL Shinsuke Mizoguchi, Kenichi Mori, Hiromitsu Mimata, and Toshitaka Shin Shinsuke MizoguchiShinsuke Mizoguchi More articles by this author , Kenichi MoriKenichi Mori More articles by this author , Hiromitsu MimataHiromitsu Mimata More articles by this author , and Toshitaka ShinToshitaka Shin More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003219.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Although 5 alpha reductase inhibitors (5ARIs) can reduce prostatic volume by blocking production of dihydrotestosterone (DHT) and is widely used to treat symptomatic benign prostatic hyperplasia (BPH), the histological response to the treatment by 5ARIs is often heterogeneous and lower urinary tract symptoms can persist. Thus, a 5ARIs induced pathway related to treatment refractory is supposed to exist. To elucidate the pathways implicated to unsuccessful treatment for BPH patients, this study investigated changes in morphological and gene expression profiles in the prostate under DHT suppression using high fat diet induced obesity rat model. METHODS: Male Wistar rats at 8 weeks old were divided into four groups; rats with normal diet group (ND, n=5), rats with high fat diet induced obesity group (HFD, n=5), HFD treated by dutasteride (D, n=4), and HFD treated by dutasteride and tranilast (D+T, n=4), which is known to inhibit TGFβ. The high fat diet contains 32% fat. These rats were maintained for twelve weeks followed by two weeks treatment by oral administration of placebo or dutasteride (0.5 mg/kg) or tranilast (150 mg/kg) daily. Lateral lobes of prostate were harvested to evaluate prostatic weight, histological change and mRNA expression of IL1β and TGFβ in the prostate by qPCR. RESULTS: HFD showed significantly increased body weight, visceral fat and prostatic weight as well as significant upregulation of gene expressions in IL1β and TGFβ compared to ND. In contrast, HFD treated by dutasteride demonstrated significantly decreased prostatic weight in association with downregulation of IL1β and upregulation of TGFβ with compared to HFD with placebo. Furthermore, dutasteride administration induced prostatic fibrosis as evidenced by masson trichrome staining whereas the addition of tranilast to dutasteride suppressed prostatic tissue fibrosis in association with reduced weight of prostatic tissue and downregulation of TGFβ in group D+T compared to group D. CONCLUSIONS: This study demonstrated prostatic fibrosis in association with upregulation of TGFβ as well as decreased prostatic weight and improvement of prostatic fibrosis by TGFβ inhibition. These results suggest that TGFβ signaling has an important role in development of prostatic fibrosis under 5ARIs treatment possibly leading to treatment refractory. Therefore, TGFβ signaling pathway could be an therapeutic target for BPH. Source of Funding: JSPS KAKENHI Grant Number 20K18094 © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e69 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Shinsuke Mizoguchi More articles by this author Kenichi Mori More articles by this author Hiromitsu Mimata More articles by this author Toshitaka Shin More articles by this author Expand All Advertisement PDF downloadLoading ...